Minneapolis, MNNCT04889430Now EnrollingIRB Ready

Atypical Hemolytic Uremic Syndrome Clinical Trial in Minneapolis, MN

Access cutting-edge atypical hemolytic uremic syndrome treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Minneapolis location

Preparing your pre-screening questions...

Expert Care in Minneapolis

Access atypical hemolytic uremic syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related atypical hemolytic uremic syndrome treatment provided free

Apply for This Minneapolis Location

Check if you qualify for this atypical hemolytic uremic syndrome clinical trial in Minneapolis, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Minneapolis

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Minneapolis site if eligible
  4. 4Begin participation

About This Atypical Hemolytic Uremic Syndrome Study in Minneapolis

The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Adult patients with evidence of active thrombotic microangiopathy (TMA), including thrombocytopenia, evidence of hemolysis, and acute kidney injury
Vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections are required prior to the start of study treatment. If the patient has not been previously vaccinated, or if a booster is required, vaccine should be given according to local regulations, at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post vaccination or before vaccination is given, prophylactic antibiotic treatment must be administered at the start of study treatment and for at least 2 weeks after vaccination Main

Exclusion Criteria

Treatment with complement inhibitors, including anti-C5 antibody
ADAMTS13 deficiency (\<10% activity or \<0.1U/ml), and/or Shiga toxin-related hemolytic uremic syndrome (STx-HUS), and/or Positive direct C

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Minneapolis?

Yes, this clinical trial (NCT04889430) has an active research site in Minneapolis, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Atypical Hemolytic Uremic Syndrome Treatment Options in Minneapolis, MN

If you're searching for atypical hemolytic uremic syndrome treatment options in Minneapolis, MN, this clinical trial (NCT04889430) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced atypical hemolytic uremic syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all atypical hemolytic uremic syndrome clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Minneapolis, MN

See all heart attack clinical trials recruiting in Minneapolis — not just this study.

Browse Heart Attack Trials in Minneapolis →

Browse More Trials by Condition

Heart Attack TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Minneapolis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Minneapolis, MN